• 1
    Brechbiel MW.  Targeted alpha-therapy: past, present, future Dalton Trans. 2007; 43: 4918-4928.
  • 2
    Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 1997; 38: 1944-1950.
  • 3
    Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005; 20: 557-568.
  • 4
    Milenic DE, Garmestani K, Dadachova E, et al. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm. 2004; 19: 135-148.
  • 5
    Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2004; 10: 7834-7841.
  • 6
    Blumenthal RD, Kashi R, Stephens R, Sharkey RM, Goldenberg DM. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol Immunother. 1991; 32: 203-310.
  • 7
    Buchsbaum DJ, Rogers BE, Khazaeli MB, et al. Targeting strategies for cancer radiotherapy. Clin Cancer Res. 1999; 5 ( 10 suppl): 3048s-3055s.
  • 8
    DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res. 2005; 11( 19 pt 2): 7075s-7079s.
  • 9
    Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol. 1992; 10: 735-746.
  • 10
    Guadagni F, Schlom J, Johnston WW, et al. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst. 1989; 81: 502-512.
  • 11
    Meredith RF, Khazaeli MB, Plott WE, et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996; 2: 1811-1818.
  • 12
    Milenic DE, Garmestani K, Brady ED, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res. 2007; 13: 1926-1935.
  • 13
    Milenic DE, Garmestani K, Brady ED, et al. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2008; 14: 5108-5115.
  • 14
    Schlom J, Siler K, Milenic DE, et al. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. Cancer Res. 1991; 51: 2889-2896.
  • 15
    Siler K, Eggensperger D, Hand PH, et al. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther. 1993; 4: 163-181.
  • 16
    Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res. 2008; 14: 6154-6160.
  • 17
    Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986; 46: 850-857.
  • 18
    Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986; 46: 3118-3124.
  • 19
    Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm. 1997; 12: 305-316.
  • 20
    Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in nonsmall cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000; 27( 6 suppl 11): 53-63.
  • 21
    Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990; 45: 457-461.
  • 22
    Tom BH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro. 1976; 12: 180-191.
  • 23
    Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 1995; 55( 23 suppl): 5957s-5967s.
  • 24
    Milenic DE, Garmestani K, Chappell LL, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002; 29: 431-442.
  • 25
    Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylene-triamine-pentaacetic acids for labelling of monoclonal antibodies with the bismuth-212 a-particle emitter. J Chem Soc Perkin Trans 1. 1992: 1173-1178.
  • 26
    Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol. 2002; 29: 599-606.
  • 27
    Milenic DE, Roselli M, Mirzadeh S, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother Radiopharm. 2001; 16: 133-146.
  • 28
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951; 193: 265-275.
  • 29
    Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992; 3: 342-345.
  • 30
    Schott ME, Milenic DE, Yokota T, et al. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res. 1992; 52: 6413-6417.
  • 31
    Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986; 27: 1490-1497.
  • 32
    Kurtzman SH, Russo A, Mitchell JB, et al. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst. 1988; 80: 449-452.
  • 33
    Li Y, Abbas Rizvi SM, Blair nee Brown JM, et al. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. Int J Radiat Oncol Biol Phys. 2004; 60: 896-908.
  • 34
    Wang J, Abbas Rizvi SM, Madigan MC, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate. 2006; 66: 1753-1767.
  • 35
    Gaffar SA, Pant KD, Shochat D, Bennett SJ, Goldenberg DM. Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). Int J Cancer. 1981; 27: 101-105.
  • 36
    Munz DL, Alavi A, Koprowski H, Herlyn D. Enhancement of tumor contrast on radioimmunoscans by using mixtures of monoclonal antibody F(ab′)2 fragments. Nuklearmedizin. 1986; 25: 216-219.
  • 37
    Munz DL, Alavi A, Koprowski H, Herlyn D. Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F(ab′)2 fragments. J Nucl Med. 1986; 27: 1739-1745.
  • 38
    Ohuchi N, Simpson JF, Colcher D, Schlom J. Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer. 1987; 40: 726-733.
  • 39
    Chauhan SC, Vinayek N, Maher DM, et al. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multitargeted antibody-guided therapy. J Histochem Cytochem. 2007; 55: 867-875.
  • 40
    Milenic DE, Wong KJ, Baidoo KE, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm. 2008; 23: 619-631.